Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Steven D. Schwartz
ResearcherPublications, citations & collaboration network
Steven D. Schwartz is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 367 works, 9,405 citations, an h-index of 52 and an i10-index of 166.
367
Works
9,405
Citations
52
h-index
166
i10-index
How has Steven D. Schwartz's publication output changed over time?
ScholarIQpublication output · 2002–2023
Output grew0% over the shown period — from 1 works in 2002 to 1 in 2023.
1
1
3
1
1
1
1
1
1
1
2002200420052009201120152016201820222023
What are the most-cited papers on Steven D. Schwartz?
ScholarIQmost cited works
A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema
Emmett T. Cunningham, Anthony P. Adamis, Michael M. Altaweel, Lloyd Paul Aiello, Neil M. Bressler, Donald J. D’Amico, Mauro Goldbaum, David R. Guyer, Barrett Katz, Manju Patel, Steven D. Schwartz
Ophthalmology. 2005594 Citations
Theoretical Methods in Condensed Phase Chemistry
Steven D. Schwartz
Progress in theoretical chemistry and physics. 2002373 Citations
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
Arshad M. Khanani, Arshad M Khanani, Sunil S Patel, Giovanni Staurenghi, Ramin Tadayoni, Carl J Danzig, David A Eichenbaum, Jason Hsu, Charles C Wykoff, Jeffrey S Heier, David R Lally, Jordi Monés, Jared S Nielsen, Veeral S Sheth, Peter K. Kaiser, Julie Clark, Liansheng Zhu, Hersh Patel, Justin Tang, Dhaval Desai, Glenn J. Jaffe, Arturo Alezzandrini, A Francone, Joaquín Bafalluy, Silvina Bainttein, Jose Luna Pinto, Mario Saravia, Matko Vidosevich, Carlos Zeolite, Federico Furno Sola, Andrew Chang, Elisa E. Cornish, Thanh N. Nguyen, Oliver Findl, Anton Haas, Martina Kralinger, Stefan Sacu, Laurence Postelmans, Michel Eid Farah, Maurício Maia, Márcio Bittar Nehemy, Fareed Ali, Michael H. Brent, Michael Dollin, John R. Gonder, Amin Kherani, Andrew Merkur, Raman Tuli, Monica Marie Lopera, Francisco J. Rodríguez, Mario Bradvica, Jan Ernest, Kuldar Kalijurand, Kai Noor, Yves Cohen, Catherine Creuzot‐Garcher, F. De Bats, François Devin, Catherine Français-Maury, Laurent Kodjikian, Jean François Korobelnik, Y. Le Mer, M. Quaranta El Maftouhi, Sam Razavi, Eric H. Souied, Ramin Tadayoni, Michel Weber, Nicole Eter, Nicolas Feltgen, Salvatore Grisanti, Peter Walter, Raffael Liegl, Katrin Lorenz, Georg Spital, Siegfried Priglinger, Martin S. Spitzer, Michael Völker, Tim U. Krohne, Claudia Jochmann, Chris P. Lohmann, Carsten Framme, Ágnes Kerényi, András Papp, András Seres, Edit Tóth‐Molnár, Alexis Tsorbatzoglou, A VAJAS, Balázs Varsányi, Gábor Vogt, Asaf Bar, Eva Eting, David Hauser, Jamie Levy, Nurit Mathalone, Haia Morori-Katz, Irit Rosenblatt, Shiri Soudry-Zayit, Omert Trivizky, Francesco Bandello, Antonio P. Ciardella
The Lancet. 2023336 CitationsOPEN ACCESS
Enzymatic transition states and dynamic motion in barrier crossing
Steven D. Schwartz, Vern L. Schramm
S51309854. 2009271 CitationsOPEN ACCESS
Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld, Steven D. Schwartz, Mark S. Blumenkranz, Joan W. Miller, Julia A. Haller, James D. Reimann, William H. Greene, N. Shams
Ophthalmology. 2005223 Citations
Related on ScholarIQ
University of Arizona
Institution
A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema
Paper
Theoretical Methods in Condensed Phase Chemistry
Paper
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
Paper
Enzymatic transition states and dynamic motion in barrier crossing
Paper
Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration
Paper